Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment
Advancing CY3018, a differentiated, next-generation, CNS-penetrant sGC stimulator, in IND-enabling studies
“During the first half of the year we have made significant progress advancing our lead program CY6463 into clinical development for multiple neurological indications where we believe we could have a meaningful therapeutic impact. This positive momentum in the clinic includes the advancement of the clinical studies in participants with Alzheimer’s disease with vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) and the initiation of start-up activities for a clinical study in participants with Cognitive Impairment Associated with Schizophrenia (CIAS),” said
Recent Program and Business Updates
- ADv Clinical Trial Advancement: The
U.S. Food and Drug Administration(FDA) reviewed the Investigational New Drug (IND) application for CY6463 in ADv and notified the Company that the study may proceed. Cyclerion has initiated a 12-week Phase 2a clinical trial in patients with ADv.
- CIAS Clinical Trial Start-up: The Company received notification from the FDA that its Ph1b clinical trial in participants with CIAS may proceed and study start-up activities are ongoing.
- MELAS Clinical Trial Advancement: The exploratory 29-day open-label Phase 2a pilot study in patients with MELAS is currently enrolling and data are expected by year end 2021.
Beacon Partnership: In July, Cyclerion and Beacon Biosignals announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion’s investigational therapeutics for neurological diseases associated with cognitive impairment.
- Equity Raises: In June, Cyclerion closed a direct private sale of approximately
$18 millionof Cyclerion shares of common stock to EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners, LP, Invus, Peter Hecht, Ph.D., Lincoln Park Capital Fund, LLCand Polaris Partners. In addition, the Company received net proceeds of approximately $12.5 millionin Q2 2021 for shares sold under the ATM Offering.
- Praliciguat Out-license: In June, the Company entered into an exclusive, global license agreement with Akebia Therapeutics, Inc. for the development and commercialization of praliciguat. Under the terms of the agreement, Akebia has obtained an exclusive license to research, develop, and commercialize praliciguat globally and will be solely responsible for these activities going forward. Cyclerion is eligible to receive up to
$225Min pre-commercial milestones, including up to $15Min the first 18 months. Total potential future development, regulatory, and commercialization milestone payments could result in up to $585M. Cyclerion is also eligible to receive tiered, sales-based royalties ranging from single-digit to high-teen percentages.
- Scientific Conferences and Publications:
- In July, Cyclerion presented a poster at the Alzheimer’s
Association International Conference2021 (AAIC) highlighting the clinical trial design for a Phase 2a study of CY6463 in participants with Alzheimer’s disease with vascular pathology. In addition, Anna Marin, a researcher in the laboratory of Dr. Andrew Budsonand Dr. Katherine Turkin the Department of Neurology, Boston University School of Medicineand Center for Translational and Cognitive Neuroscience, VA Boston Healthcare System, presented results from the Cyclerion-sponsored study highlighting alpha peak frequency and N200 latency as predictors of neuropsychological performance in a memory disorders clinic.
- In May, Cyclerion announced the publication of preclinical data for CY6463 in Frontiers in Pharmacology. The publication includes preclinical pharmacology data with CY6463 and, along with decades of research, highlights the crucial role of the sGC pathway in brain physiology and cognition. Across a range of preclinical models, administration of CY6463 resulted in physiologically relevant drug levels in cerebrospinal fluid and led to improvements in neuronal function, neuroprotection, and cognitive performance.
- In April, Cyclerion hosted a webinar and provided an update on its clinical programs for its first-in-class, CNS-penetrant sGC stimulator, CY6463, in ADv, MELAS and CIAS. The event included neuropsychiatric key opinion leader, Andreas Reif, M.D., Chair, Department of Psychiatry, University Hospital Frankfurt, who discussed the sGC pathway and its role in cognitive function and CIAS. Cyclerion also introduced its latest development candidate, CY3018, a differentiated, next-generation, CNS-penetrant sGC stimulator.
- In July, Cyclerion presented a poster at the Alzheimer’s
- Board of Directors Transitions: In April, the Company announced that
Errol De Souza, Ph.D., was appointed to the Company’s board of directors. Dr. De Souzais currently a member of the board of directors of Royalty Pharma and Catalyst Biosciences and executive chairman of Bionomics Limited. Previously, Dr. De Souzafounded Neurocrine Biosciences, Inc., served as CEO of numerous publicly traded and private companies, including Biodel, Inc., Synaptic Pharmaceutical Corp., Archemix Corp.and Neuropore Therapies, Inc.In addition, he led CNS R&D at DuPont Merck and US R&D at Aventis. Dr. De Souzareceived a B.A. in physiology and a Ph.D. in endocrinology from the University of Toronto.
Second Quarter 2021 Financial Results
- Cash Position: Cash, cash equivalents, and restricted cash balance on
June 30, 2021was approximately $70 million, as compared to approximately $45 millionon March 31, 2021.
- Research & Development Expenses: Research and development expenses were approximately
$12.1 millionfor the second quarter of 2021, as compared to approximately $13.8 millionfor the second quarter of 2020. The decrease of approximately $1.7 millionwas driven by a decrease of approximately $4.2 millionin salaries, stock-based compensation, and other employee-related expenses due to lower average headcount, a net increase of approximately $2.3 millionof facilities and operating costs allocated to research and development primarily due to $4.2 millionof non-cash write-off of leasehold improvements partially offset by $1.9 millionreduction in the Company’s total leased premises expense, and a net increase of approximately $0.2 millionin external research costs, primarily related to the start-up costs for CY6463 in CIAS and ADv, offset by the completion of praliciguat and olinciguat trials in the prior year.
- General and Administrative Expenses: General and administrative expenses were approximately
$6.2 millionfor the second quarter of 2021, as compared to approximately $6.6 millionfor the second quarter of 2020. The decrease of approximately $0.4 millionwas primarily driven by a decrease of approximately $1.3 millionin salaries, stock-based compensation, and other employee-related expenses due to lower average headcount, and a decrease of approximately $1.2 millionin facilities and other operating costs, partially offset by an increase of approximately $2.1 millionof non-cash write-off of leasehold improvements.
- Net Loss: Net loss was approximately
$16.2 millionfor the second quarter of 2021, as compared to $19.5 millionfor the second quarter of 2020.
CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. Nitric oxide (NO) is one of several fundamental neurotransmitters, but it has yet to be leveraged for its full CNS therapeutic potential. CY6463 stimulates sGC, a signaling enzyme that responds to the presence of NO, to enhance the body’s natural ability to produce cyclic guanosine monophosphate (cGMP), an important signaling molecule that regulates diverse and critical biological functions in the CNS including neuronal function, neuroinflammation, cellular bioenergetics, and vascular dynamics. Impaired NO-sGC-cGMP signaling is believed to play an important role in the pathogenesis of many neurodegenerative and neuropsychiatric diseases. Agents that stimulate sGC to produce cGMP may compensate for deficient NO signaling.
About Cyclerion Therapeutics
Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties and include, among other things, whether the praliciguat out-license will result in the creation of any therapies for the treatment of patients with kidney disease; the uncertain utility, development, promise, and commercialization of praliciguat; and whether any development, regulatory and commercialization milestones or royalty payments provided for in the agreement with Akebia will be achieved. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in our 2020 Form 10-K filed on February 25, 2021, and our subsequent
Kendall Investor Relations
Source: Cyclerion Therapeutics, Inc.